Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Randall

MOHS-Micrographic Surgery West Lafayette, IN Medical Doctor

NPI 1326076530 CMS profile 771161

124 Sagamore Pkwy W, West Lafayette, IN 47906

Open in the dashboard

General payments

$5,945

436 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,982,958 paid to institutions, not to them · program years 2019–2025

Through program year 2025, John Randall of West Lafayette, IN is reported in the CMS Open Payments database as having received $5,945 across 436 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,982,958 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $919 71
2024 General $1,024 78
2023 General $578 45
2022 General $869 60
2021 General $1,189 81
2020 General $665 50
2019 General $701 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Randall
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to John Randall were reported at $919. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year John Randall MOHS-Micrographic Surgery median Middle half National median
2019 $701 $316 $106–$785 $163
2020 $665 $162 $68–$412 $114
2021 $1,189 $243 $87–$654 $132
2022 $869 $300 $102–$887 $149
2023 $578 $364 $125–$1,010 $160
2024 $1,024 $445 $142–$1,108 $164
2025 $919 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,516 217 payments
  2. AbbVie, Inc. $1,124 88 payments
  3. Janssen Biotech, Inc. $768 50 payments
  4. E.R. Squibb & Sons, L.L.C. $188 11 payments
  5. Regeneron Healthcare Solutions, Inc. $181 8 payments
  6. Genentech USA, Inc. $118 6 payments
  7. LEO Pharma Inc. $116 6 payments
  8. Galderma Laboratories, L.P. $103 5 payments
  9. Genzyme Corporation $87 5 payments
  10. Amgen Inc. $85 5 payments
  11. Other $661 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,597 431 payments
  2. Education $348 5 payments
Products named General payments · program years 2019–2025
  1. COSENTYX Immunology $912 79 payments
  2. COSENTYX Dermatology $836 81 payments
  3. TREMFYA $556 32 payments
  4. SKYRIZI $551 41 payments
  5. RINVOQ $396 31 payments
  6. STELARA $339 36 payments
  7. HUMIRA $309 21 payments
  8. COSENTYX Dermatology $225 14 payments
  9. SOTYKTU $221 13 payments
  10. SIMPONI ARIA $212 18 payments
  11. Other $2,192 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

820

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$687,196

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

22%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erivedge Vismodegib Brand 28 $405,051
Cosentyx Sensoready (2 Pens) Secukinumab Brand 22 $163,237
Otezla Apremilast Brand 15 $77,030
Santyl Collagenase Clostridium Hist. Brand 15 $20,395
Tavaborole Generic 15 $6,181
Ammonium Lactate Generic 142 $2,587
Clobetasol Propionate Generic 35 $2,002
Fluorouracil Generic 22 $1,549
Betamethasone Dipropionate Generic 26 $1,216
Metronidazole Generic 22 $1,075

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$1,673,452

Of which drugs: $44,759

Medicare patients

1,360

Average age 76

Services billed

16,857

667 women, 693 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 32%
Ischemic heart disease 30%
Chronic kidney disease 27%
Atrial fibrillation 18%
Depression 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 39 73 $21,905
Oasis wound matrix, per square centimeter Q4102 Office 85 1,177 $11,652

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $346
$346 22 —
RINVOQ
  • AbbVie, Inc. $134
$134 — —
SKYRIZI
  • AbbVie, Inc. $132
$132 — —
TREMFYA
  • Janssen Biotech, Inc. $120
$120 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $53
  • Celgene Corporation $34
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record